Abstract:

In 2022, the National Cancer Center released the latest data. The results show that the incidence of gynecologic tumors in China shows an upward trend. Taking ovarian cancer as an example, the annual number of new cases is 57 200, with a crude incidence rate of 8.47/100 000, and the annual number of death cases is 27 200, with a crude mortality rate of 4.04/100 000, and the morbidity and mortality are higher than the world standard rates (5.59/100 000 and 2.45/100 000, respectively). Physicians practicing gynecologic oncology in China face greater challenges. Patients with early gynecologic tumors have better overall outcomes after standardized treatment. However, limited treatment modalities and high recurrence rates often lead to poorer prognosis for patients with advanced, recurrent or metastatic gynecologic malignancies. In recent years, emerging treatments such as targeted therapy, immunotherapy and antibody-drug conjugate have ushered in a new era in the treatment of gynecologic tumors, bringing more hope to patients. This article summarized the significant advances in gynecological tumor surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy and biomarkers in the past year, so as to better guide the individualized and precise treatment of gynecologic tumors.

Key words: Cervical cancer, Ovarian cancer, Endometrial cancer, Vulvar cancer, Progress in diagnosis and treatment